Sameer Uz Zaman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sameer Uz Zaman has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ratnesh Sinha
Department of Community Medicine, ESIC Medical College and Hospital, Ranchi, Jharkhand, India
2 shared publications - Sayan Kumar Das
Department of Pharmacology, Apollo Institute of Medical Sciences and Research, Chittoor, India
2 shared publications - Agus Fitriangga
Department of Community Medicine, Faculty of Medicine, Universitas Tanjungpura, Pontianak, Indonesia
1 shared publication - Alex Alex
Department of Anatomy, Faculty of Medicine, Universitas Tanjungpura, Pontianak, Indonesia
1 shared publication Alok Singh
Department of Naturopathy & Yogic Sciences, Faculty of Naturopathy and Yogic Sciences, SGT University, Gurugram, Haryana, India
1 shared publication- Ananyan Sampath
Medicine, All India Institute of Medical Sciences, Bhopal, Bhopal, IND
1 shared publication
Latest Publications
- Open Access
- 2 July 2026
- Published by Taylor & Francis in Medical Teacher
- p. 1-2
When what we can count is all that counts
- 2 July 2026
- Published by Taylor & Francis in Medical Teacher
- p. 1-2
Open AccessWhen what we can count is all that counts
- 16 June 2026
- Published by Bentham Science Publishers Ltd. in Anti-Infective Agents
- Vol. 24, 1-12
Cefepime/Enmetazobactam: A Novel β-Lactam/β-Lactamase Inhibitor Combination for Multidrug-Resistant Gram-Negative Infections
Introduction: Antimicrobial Resistance (AMR) among gram-negative pathogens poses a major global threat, with limited new antibacterials approved. Cefepime/ enmetazobactam, a novel β-lactam/β-lactamase inhibitor, restores cefepime activity against extendedspectrum β-lactamase (ESBL)-producing Enterobacterales and other multidrug-resistant gramnegatives, offering an option for complicated Urinary Tract Infections (cUTIs). Methods: This narrative review synthesises phase 1–3 trials, in vitro surveillance, pharmacokinetic data, and network meta-analyses on cefepime/enmetazobactam versus comparators in cUTIs and related infections. Results: Enmetazobactam inactivates class A β-lactamases (KPC-2, CTX-M-15, SHV-1), boosting cefepime susceptibility from 2% to 98% against ESBL-Enterobacterales; activity is robust against AmpC-producers but limited against metallo-β-lactamases, OXA-types, Acinetobacter baumannii, and Stenotrophomonas maltophilia. In the phase 3 ALLIUM trial (n=1034), cefepime/enmetazobactam achieved superior composite cure rates versus piperacillin/ tazobactam (79.1% vs 58.9%; difference 21.2%) in cUTIs/pyelonephritis, including ESBLsubgroups. Network meta-analyses confirm outcomes comparable to carbapenems, with similar safety (mainly hepatic/infusion events). Discussion: Cefepime/enmetazobactam shows favourable outcomes as a newer agent for ESBLcUTIs compared to piperacillin/tazobactam, although evidence remains cUTI-focused with modest ESBL representation and spectrum gaps against key resistant pathogens. Pathogendirected use within stewardship is essential. Conclusion: Cefepime/enmetazobactam may contribute to AMR management for susceptible cUTIs/pyelonephritis and HAP/VAP, but its role beyond these indications will depend on further trials in high-risk ESBL/carbapenemase infections.
- 16 June 2026
- Published by Bentham Science Publishers Ltd. in Anti-Infective Agents
- Vol. 24, 1-12
Cefepime/Enmetazobactam: A Novel β-Lactam/β-Lactamase Inhibitor Combination for Multidrug-Resistant Gram-Negative Infections
Introduction: Antimicrobial Resistance (AMR) among gram-negative pathogens poses a major global threat, with limited new antibacterials approved. Cefepime/ enmetazobactam, a novel β-lactam/β-lactamase inhibitor, restores cefepime activity against extendedspectrum β-lactamase (ESBL)-producing Enterobacterales and other multidrug-resistant gramnegatives, offering an option for complicated Urinary Tract Infections (cUTIs). Methods: This narrative review synthesises phase 1–3 trials, in vitro surveillance, pharmacokinetic data, and network meta-analyses on cefepime/enmetazobactam versus comparators in cUTIs and related infections. Results: Enmetazobactam inactivates class A β-lactamases (KPC-2, CTX-M-15, SHV-1), boosting cefepime susceptibility from 2% to 98% against ESBL-Enterobacterales; activity is robust against AmpC-producers but limited against metallo-β-lactamases, OXA-types, Acinetobacter baumannii, and Stenotrophomonas maltophilia. In the phase 3 ALLIUM trial (n=1034), cefepime/enmetazobactam achieved superior composite cure rates versus piperacillin/ tazobactam (79.1% vs 58.9%; difference 21.2%) in cUTIs/pyelonephritis, including ESBLsubgroups. Network meta-analyses confirm outcomes comparable to carbapenems, with similar safety (mainly hepatic/infusion events). Discussion: Cefepime/enmetazobactam shows favourable outcomes as a newer agent for ESBLcUTIs compared to piperacillin/tazobactam, although evidence remains cUTI-focused with modest ESBL representation and spectrum gaps against key resistant pathogens. Pathogendirected use within stewardship is essential. Conclusion: Cefepime/enmetazobactam may contribute to AMR management for susceptible cUTIs/pyelonephritis and HAP/VAP, but its role beyond these indications will depend on further trials in high-risk ESBL/carbapenemase infections.
- Open Access
- 22 May 2026
- Published by Elsevier in Clinical Therapeutics
- Vol. 48 (8) , 790-797
Efficacy and Safety of Inhalational Insulin Compared With Rapid-Acting Insulin Analogs: A Systematic Review and Meta-Analysis
- 22 May 2026
- Published by Elsevier in Clinical Therapeutics
- Vol. 48 (8) , 790-797
Open AccessEfficacy and Safety of Inhalational Insulin Compared With Rapid-Acting Insulin Analogs: A Systematic Review and Meta-Analysis
- 11 February 2026
- Published by Elsevier in Indian Journal of Tuberculosis
- Vol. 73 (2) , 261-269
Prevalence of lost to follow-up in drug-sensitive TB patients in WHO SEAR countries: A systematic review and meta-analysis
- 11 February 2026
- Published by Elsevier in Indian Journal of Tuberculosis
- Vol. 73 (2) , 261-269
Prevalence of lost to follow-up in drug-sensitive TB patients in WHO SEAR countries: A systematic review and meta-analysis
- 1 March 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (2) , 201-213
Genetic Predisposition for the Development of Lamotrigine-Induced Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: a Systematic Review and Meta-Analysis
Studies report an association between the expression of HLA alleles and lamotrigine (LTG)-induced Stevens–Johnson syndrome (SJS). This systematic review and meta-analysis evaluates the association ...
- 1 March 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (2) , 201-213
Genetic Predisposition for the Development of Lamotrigine-Induced Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: a Systematic Review and Meta-Analysis
Studies report an association between the expression of HLA alleles and lamotrigine (LTG)-induced Stevens–Johnson syndrome (SJS). This systematic review and meta-analysis evaluates the association ...